West Nile virus (WNV) and Usutu virus (USUV) are closely related mosquito-borne viruses (genus *Flavivirus*; family *Flaviviridae*). WNV infection in humans may result in disease of varying severity, from West Nile fever (WNF) to possibly lethal West Nile neuroinvasive disease (WNND) \[[@r1]\]. Human infections with USUV are usually asymptomatic or occasionally associated with rash \[[@r2]\]; severe disease is rarely seen and occurs mainly in immunocompromised patients \[[@r3],[@r4]\]. In 2018, the highest ever number of WNV and USUV infections were detected in Austria.

Human West Nile virus and Usutu virus infections in Austria, 2009--2018
=======================================================================

The first three human West Nile disease (WND) cases were identified in eastern Austria in 2009 and 2010; two cases of WNND and one case of WNF \[[@r5]\]. Since then, autochthonous human WND cases have been diagnosed every year, with the exception of 2011--2013, when only imported WNV cases were detected ([Table 1](#t1){ref-type="table"}).

###### Number of diagnosed human West Nile and Usutu virus infections, Austria, 2009--2018

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Year        West Nile virus infections   Reference   Usutu virus infections   Reference                                                   
  ----------- ---------------------------- ----------- ------------------------ ----------- -------- -------- ----------------- ----------- --------
  2009        1                            1           0                        ND          0        2        \[[@r5]\]         ND          NA

  2010        1                            0           0                        ND          0        1        ND                NA          

  2011        0                            0           0                        ND          0        0        NA                ND          NA

  2012        0                            0           0                        ND          3        3        NA                ND          NA

  2013        0                            0           0                        ND          0        0        NA                ND          NA

  2014        1                            0           0                        1           0        2        \[[@r7],[@r8]\]   0           NA

  2015        1                            0           1                        5           0        7        \[[@r6]\]\        0           NA
                                                                                                              \                             
                                                                                                              \[[@r9]\]                     

  2016        1                            1           0                        3           0        5        1                 \[[@r9]\]   

  2017        2                            2           1                        1           1        7        6                             

  2018        4                            11          0                        6           6        27       NA                18          NA

  **Total**   **11**                       **15**      **2**                    **16**      **10**   **54**   **NA**            **25**      **NA**
  --------------------------------------------------------------------------------------------------------------------------------------------------

Asympt: asymptomatic; NA: not applicable; ND: not done; WNF: West Nile fever; WNND: West Nile neuroinvasive disease; WNV: Nest Nile virus.

Between 28 June and 17 September 2018, 27 cases of human WNV infections were recorded of which 21 were locally acquired. Four cases were WNND, 11 cases were WNF, six were WNV infections detected by blood donation screening and six cases were associated with travels to Serbia (n = 2), Italy (n = 1), Greece (n = 1), Hungary (n = 1), and Croatia (n = 1). USUV infections were identified in 18 of 31,598 blood donations tested ([Table 1](#t1){ref-type="table"}). All autochthonous WNV and USUV infections were acquired in eastern Austria ([Figure 1](#f1){ref-type="fig"}).
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In Austria, human, veterinary and entomological surveillances to detect WNV and USUV include seasonal testing of blood donations originating from endemic areas, detailed sample examination of humans and equids with neurological symptoms, passive ornithological monitoring as well as regular, nationwide mosquito surveillance (for details see \[[@r6]\]).

In 2014, the Blood Service for Vienna, Lower Austria and Burgenland of the Austrian Red Cross introduced an automated nucleic acid test (NAT) on the cobas 8800 system (cobas WNV assay; Roche, Rotkreuz, Switzerland) for all blood donated between 1 June and 30 November each year. Already in the first year of screening, one WNV-positive donation was identified \[[@r7],[@r8]\] as well as one clinical WNND case ([Table 1](#t1){ref-type="table"}). In the 2015/16 \[[@r6]\] and 2017 seasons, further clinical WNV cases were diagnosed and positive blood donations were identified \[[@r9]\]. To date, no WND associated fatalities have occurred in Austria. Increasing USUV activity in birds in recent years in Austria was reflected in human infections, when one of four, and six of seven flavivirus NAT-positive blood donations turned out to be USUV positive and not WNV positive in 2016 and 2017, respectively ([Table 1](#t1){ref-type="table"}) \[[@r9]\].

In 2018, overall, 15 patients and three blood donors showed signs and symptoms compatible with WNV infection ([Table 2](#t2){ref-type="table"}). Three of four patients with WNND were male and the median age was 62 years (range 58--77). Of the 11 WNF cases, six were male and the median age was 51 years (range 33--87). The overall median age of the blood donors was 56 years (range 23--71) with no difference between WNV and USUV-positive persons. Five of six and 14 of 18 WNV and USUV-positive blood donors, respectively, were male. Of the 18 USUV infections identified from blood donations tested, 16 donors remained asymptomatic, one developed a rash and one donor did not disclose information. One blood donor had a dual infection with WNV and USUV ([Table 2](#t2){ref-type="table"}).

###### Details of autochthonous human West Nile and Usutu virus infections, Austria, 2018

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cases              Main symptoms                    Month of symptom onset/ blood donation   Cobas WNV assay^a^   WNV\        USUV\       WNV NT   USUV NT
                                                                                                                    RT-PCR^b^   RT-PCR^b^            
  ------------------ -------------------------------- ---------------------------------------- -------------------- ----------- ----------- -------- ---------
  **WNND**                                                                                                                                           

  1                  Disorientation, aphasia          August                                   ND                   Pos         Neg         240      40

  2                  Disorientation, coma             September                                ND                   Pos         Neg         640      60

  3                  Fever, stiff neck                August                                   ND                   Pos         Neg         160      20

  4                  Dysarthria, limb weakness        September                                ND                   Neg         Neg         240      60

  **WNF**                                                                                                                                            

  1                  Fever, rash, fatigue, headache   August                                   ND                   Pos         Neg         960      160

  2                  Fever, rash, diarrhoea           August                                   ND                   Pos         ND          320      80

  3                  Fever, rash                      August                                   ND                   Pos         Neg         640      60

  4                  Rash                             August                                   ND                   Pos         ND          ND       ND

  5                  Fever, rash                      August                                   ND                   Pos         ND          40       30

  6                  Fever, rash                      August                                   ND                   Pos         ND          320      120

  7                  Rash, ocular pain                August                                   ND                   Pos         ND          320      40

  8                  Fever, fatigue, muscle aches     August                                   ND                   Pos         ND          480      60

  9                  Rash, fatigue                    August                                   ND                   Neg         Neg         240      60

  10                 Fever, rash                      August                                   ND                   Pos         ND          120      \< 20

  11                 Fever, fatigue                   August                                   ND                   Pos         Neg         320      \< 20

  **Blood donors**                                                                                                                                   

  **WNV**                                                                                                                                            

  BD2                Rash, fatigue, headache^c^       August                                   Pos (30.4)           Pos         Neg         480      30

  BD4                Rash, fatigue^d^                 August                                   Pos (40.0)           Pos         Neg         1,920    160

  BD9                Fatigue, joint aches^c^          August                                   Pos (30.8)           Pos         Neg         240      80

  BD17               Asympt                           August                                   Pos (30.0)           Pos         Neg         160      60

  BD18               Asympt                           August                                   Pos (39.4)           Pos         Neg         240      160

  **WNV/USUV**                                                                                                                                       

  BD7                Asympt                           August                                   Pos (34.1)           Pos         Pos         960      120

  **USUV**                                                                                                                                           

  BD1                Asympt                           June                                     Pos (38.7)           Neg         Pos         \< 20    40

  BD3                Rash^c^                          August                                   Pos (37.6)           Neg         Pos         60       160

  BD5                Asympt                           August                                   Pos (39.4)           Neg         Pos         ND       ND

  BD6                Asympt                           August                                   Pos (37.1)           Neg         Pos         80       240

  BD8                Asympt                           August                                   Pos (44.0)           Neg         Pos         \< 20    80

  BD10               Asympt                           August                                   Pos (35.3)           Neg         Pos         ND       ND

  BD11               Asympt                           August                                   Pos (38.8)           Neg         Pos         30       120

  BD12               Asympt                           August                                   Pos (40.7)           Neg         Pos         \< 20    160

  BD13               Asympt                           August                                   Pos (38.4)           Neg         Pos         \< 20    40

  BD14               No information                   August                                   Pos (39.3)           Neg         Pos         ND       ND

  BD15               Asympt                           August                                   Pos (36.5)           Neg         Pos         ND       ND

  BD16               Asympt                           August                                   Pos (36.8)           Neg         Pos         20       40

  BD19               Asympt                           August                                   Pos (36.6)           Neg         Pos         20       120

  BD20               Asympt                           August                                   Pos (42.1)           Neg         Neg         \< 20    80

  BD21               Asympt                           August                                   Pos (41.7)           Neg         Neg         \< 20    80

  BD22               Asympt                           September                                Pos (40.0)           Neg         Pos         ND       ND

  BD23               Asympt                           Septenber                                Pos (38.6)           Neg         Pos         40       240
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Asympt: asymptomatic; ND: not done; Neg: negative; NT: Neutralizing antibody titer in first or follow-up serum sample; Pos: positive; USUV: Usutu virus; WNF: West Nile fever; WNND: West Nile neuroinvasive disease; WNV: West Nile virus.

^a^Nucleic acid test performed in plasma samples. Cq values obtained with pools of 19 donations are shown in brackets.

^b^WNV and USUV PCR performed in plasma, whole blood, serum, urine and/or cerebral spinal fluid.

^c^Symptoms occurred 1--3 days after blood donation. The donors were viremic but asymptomatic.

^d^Mild symptoms 2 days before blood donation, but asymptomatic at blood donation.

All infections diagnosed up to 24 October 2018 are included.

WNV and USUV PCRs, as well as neutralisation tests, were performed as previously described \[[@r5],[@r6],[@r9]\].

Sequencing information
======================

Sequencing of short fragments of the WNV C/prM (294nts) and USUV NS5 (396nts) genes enabled exact identification of the detected viruses. This analysis revealed that all WNV strains belonged to lineage 2 with a 98.98--100% identity to the Austrian strain BD2/2016 \[[@r6]\] (GenBank accession number MF984347). All but two USUV strains belonged to the currently in Austria most widespread 'Europe 2' lineage showing 99.84--100% identity to European 2 sequences of Hungarian blackbirds (e.g. GenBank accession number MF063048) and an Austrian blood donor sequence from 2017 (GenBank accession number MF991886)([Figure 2](#f2){ref-type="fig"}). The two USUV strains from BD3 and BD16, however, clustered within the 'Africa 3' lineage and were 99.52-99.84% identical to the African 3 sequences of birds from Germany and The Netherlands (e.g. GenBank accession numbers KY294723, KY128482)([Figure 2](#f2){ref-type="fig"}).

![Phylogram demonstrating the genetic relationships among Usutu viruses based on partial (396 nts) NS5 protein coding nucleotide sequences](1800545-f2){#f2}

Discussion
==========

With 21 locally-acquired and six imported human WNV infections the 2018 transmission season has been the most relevant since the introduction of the aetiological lineage 2 WNV to Austria in 2008 \[[@r10],[@r11]\]. The number of autochthonous human infections identified so far in 2018 has almost reached the cumulative number diagnosed in the past 10 years (2008--2017) in eastern Austria (23 locally-acquired human infections). In addition, obligatory seasonal blood donation screening and subsequent testing by virus-specific RT-PCR assays revealed 18 USUV infections among blood donors, which is the highest number of human infections reported since the emergence of USUV in Austria in 2001 \[[@r12]\]. An early start of the WNV/USUV transmission season was observed in Austria in 2018, which (at least for WNV) was also seen in other European countries \[[@r13],[@r14]\] and might have been associated with favourable environmental and climatic conditions for an early upsurge of the vector population \[[@r14]\].

One blood donor was found to have a double infection with both WNV and USUV for the first time. While the central European lineage 2 \[[@r15]\] was the causative WNV strain in all sequenced cases, two different USUV lineages were identified in the blood donors. The vast majority were infected with USUV lineage 'Europe 2', which is currently the dominating USUV strain in Austria \[[@r9],[@r16]\]. Two donors, however, were infected with the USUV 'Africa 3' lineage, which is also circulating in Austria on a smaller scale (unpublished data). Follow-up investigations of WNV positive blood donors revealed mild symptoms e.g. rash and fatigue in three of the six cases a few days before or after donating blood, whereas 16 of 18 USUV-RNA positive donors did not report any symptoms; one donor reported a rash and for one case no information was available. Although USUV seems to be less pathogenic for humans than WNV, the virus might cause severe disease in immunocompromised patients \[[@r3],[@r4]\] or might be involved in other neurologic disorders such as idiopathic facial paralysis, as recently reported from France \[[@r17]\].

USUV is spreading in Europe, which may lead to increased numbers of human infections. In countries with blood donation testing for flavivirus RNA, health authorities should be aware that positive WNV screening results could be due to USUV infections and have to be further differentiated. In addition, countries where blood donation testing is not performed for flaviviruses, USUV might be transmitted through contaminated blood units. Although no transfusion-associated USUV infection has been reported so far, it is of utmost importance to further investigate the clinical relevance of USUV infections.
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